newsfilter
← Latest News
Business Wire·

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve